Clinical Trial: A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Early-Line Treatment in Subjects With Multiple Myeloma

U.S., July 19 -- ClinicalTrials.gov registry received information related to the study (NCT07073547) titled 'A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Early-Line Treatment in Subjects With Multiple Myeloma' on July 10.

Brief Summary: This trial is a phase 1, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CAR T-cell therapy, in early-line treatment in subjects with Multiple Myeloma.

Study Start Date: Aug. 11

Study Type: INTERVENTIONAL

Condition: Newly Diagnosed Multiple Myeloma Relapsed Refractory Multiple Myeloma

Intervention: BIOLOGICAL: GC012F (AZD0120)

GC012F (AZD0120) is a BCMA/CD19 dual CAR T cell product under investigation for early-line treatment in subjects with Multiple My...